New York

Who we are

  • February 24, 2025
    A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
  • August 23, 2024
    A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia
  • July 8, 2024
    Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
  • April 24, 2024
    Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
  • April 24, 2024
    A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
  • February 29, 2024
    A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
  • February 7, 2024
    Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
  • February 5, 2024
    ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)
  • January 17, 2024
    A Phase 0 Study of EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
  • January 17, 2024
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer